Teradyne, Inc. filings document an operating company with common stock traded on Nasdaq under TER and businesses in automated test equipment and advanced robotics. Form 8-K reports cover quarterly operating and financial results across Semiconductor Test, Product Test, and Robotics, along with material events such as annual meeting vote results and executive-transition or compensation arrangements.
Proxy materials describe board elections, advisory compensation votes, auditor ratification, executive compensation, equity-award reporting, and related governance matters. The filings also provide capital-structure details, including Teradyne's common stock class, and formal exhibits tied to earnings releases and other disclosure events.
Teradyne director and President & CEO Gregory Stephen Smith reported a sale of 554 shares of Teradyne common stock on 09/12/2025 at a price of $115 per share. The Form 4 shows 96,438.995 shares remained beneficially owned by Mr. Smith after the reported sale. The filing states the shares were sold under a sales plan adopted February 4, 2025 that was intended to comply with Rule 10b5-1, indicating the transaction followed a prearranged insider trading plan. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Jean Pierre Hathout filed an initial Form 3 reporting beneficial ownership in Teradyne, Inc. (TER) on 09/02/2025. The filing shows 9,551 shares beneficially owned, consisting of 1,713 vested common shares and 7,838 restricted stock units (RSUs) awarded under the companys 2006 Equity and Cash Compensation Incentive Plan. The RSUs convert one-for-one to common shares and vest on defined schedules from 2026 through 2028. Hathout is identified as an officer (President, Teradyne Robotics) and director.
Mercedes Johnson, a director of Teradyne, Inc. (TER), reported a sale of company stock under a pre-established trading plan. The Form 4 shows a transaction on 09/05/2025 in which 625 shares of Teradyne common stock were sold at a price of $120.06 per share. After the sale, the reporting person directly beneficially owned 10,738 shares and indirectly beneficially owned 1,876 shares held by a trust for which she is trustee and sole beneficiary.
The filing notes the sale was made pursuant to a 10b5-1 plan adopted on February 3, 2025. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/09/2025.
Form 144 notice for Teradyne, Inc. (TER): The filer reports an intended sale of 625 common shares through Fidelity Brokerage Services on 09/05/2025 with an aggregate market value of $75,037.50. The securities were acquired by restricted stock vesting on 05/09/2024 and were received as compensation. The filing also discloses prior sales by the same person this year: 1,875 shares sold 07/30/2025 for $198,243.75 and 625 shares sold 08/05/2025 for $66,250.00. The filing states the seller represents there is no undisclosed material adverse information. The total shares outstanding reported are 159,073,532 and the planned sale is on NASDAQ.
Teradyne, Inc. disclosed terms related to an executive separation and upcoming filings. The executive will remain subject to non-compete, non-solicitation and non-disparagement covenants for 12 months following his last day of employment, provided he complies with those restrictions. He is also eligible for a pro-rated 2025 annual cash bonus based on actual performance, which the company expects to pay in early 2026. The company references a Form 10-Q for the quarter ended September 28, 2025, and the document is signed by Ryan E. Driscoll, V.P., General Counsel and Secretary.
Reporting person: Gregory Stephen Smith, who serves as President and CEO and a director of Teradyne, Inc. (TER), reported an insider sale on Form 4. The transaction occurred on 08/12/2025 and was reported on a Form 4 signed by an attorney-in-fact on 08/14/2025. The filing shows 554 shares of Teradyne common stock were sold at a price of $106 per share pursuant to a pre-established Rule 10b5-1 sales plan adopted on February 4, 2025. After the reported sale, the filing shows the reporting person beneficially owns 96,992.995 shares directly.
Teradyne's Form 144 reports a proposed sale of 554 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $58,724 and an approximate sale date of 08/12/2025 on NASDAQ. The filing lists total shares outstanding as 159,073,532, indicating the position is very small relative to the company's capitalization. The securities were acquired by restricted stock vesting on 01/27/2025, and the consideration is recorded as compensation.
The notice also records a prior sale of the same 554 shares on 07/30/2025 for $58,574.42. The form includes the standard Rule 144 representation regarding absence of undisclosed material adverse information and a field for Rule 10b5-1 plan adoption if applicable, though no plan adoption date is provided in the filing.
SEC Form 4 – Teradyne, Inc. (TER)
- Director Mercedes Johnson sold 625 common shares on 08/05/2025 at $106 per share.
- The disposition was made pursuant to a Rule 10b5-1 trading plan adopted 02/03/2025, indicating a pre-scheduled, compliance-driven sale.
- Post-transaction ownership: 11,363 shares held directly; an additional 1,876 shares held indirectly through The Mercedes Johnson Trust.
No derivative securities were reported and no other transactions were disclosed. The 625-share sale represents a small fraction of the director’s total holdings; therefore, the filing appears routine with limited immediate investment significance.
Teradyne, Inc. (TER) filed a Form 144 indicating that shareholder Mercedes Johnson plans to sell up to 625 common shares through Fidelity Brokerage on or after 08/05/2025. At the latest reported market price, the sale would total roughly $66,250. The shares originated from a 05/09/2024 restricted-stock vesting transaction and were received as compensation.
Johnson has already sold 1,875 shares for $198,243.75 during the past three months. The proposed sale represents 0.0004 % of TER’s 159,073,532 shares outstanding, suggesting minimal dilution or trading-volume impact. No material adverse information was reported, and the signer affirms compliance with Rule 10b5-1 and other SEC requirements.